Objectives: Copy number variants (CNVs) have been recognized as a source of genetic variation that contributes to disease phenotypes. Alzheimer disease (AD) has high heritability for occurrence and age at onset (AAO). We performed a cases-only genome-wide CNV association study for age at onset of AD.
CNVs confer a novel genetic marker map assaying association signals that are not detectable by SNPs. 6 With the advent of microarray technology allowing genome-wide ascertainment of CNVs, disease associations have been reported in schizophrenia, systemic lupus erythematosus, and HIV susceptibility. [7] [8] [9] CNVs influence gene expression, phenotypic variation, and adaptation by altering gene dosage and genome organization. 5, 9 In this study, we performed a genome-wide CNV association study to identify loci that modify AAO of AD.
METHODS Subject cohorts. The discovery (n ϭ 40) and replication (n ϭ 507) cohorts met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for probable AD. 10 The discovery cohort was ascertained at the AD and Memory Disorders Center of Baylor College of Medicine. 11 Cases found to carry the APOE4/4 genotype were excluded from the discovery cohort to diminish the variance in AAO caused by the APOE4 allele. The replication dataset was ascertained as part of the Texas Alzheimer Research Consortium project. 12 Further description of the cohorts is available in appendix e-1 and table e-1 on the Neurology ® Web site at www.neurology.org.
Standard protocol approvals, patient consents. The Institutional Review Board of all participating sites approved the study. Informed consent was obtained from each subject and their legally authorized representative, as subjects with dementia constitute a vulnerable population. AAO phenotyping. AAO was determined with 2 standardized methods in both cohorts: 1) caregiver estimate by prompted standard question regarding onset of symptoms and 2) physician estimate of duration of illness using a standardized and validated structured interview with landmark event to facilitate recall. 13 Detection of CN variation association with AAO. Discovery cohort. The discovery study was exploratory, as there were no available data on CNV and genome-wide association study in AD. The post hoc power analysis for a Weibull regression using our empirical results from this study to determine a distribution of ages and CNV states showed a power of between 40% and 60% to detect an association of this effect size for a risk allele frequency of between 5% and 10% in a sample size of 40.
Array comparative genome hybridization (aCGH) was used to detect genomic CN variation at a high resolution level with an 8.9-kb overall median probe spacing (Agilent Human Genome CGH microarray 244A). The normalized log-ratio data were generated by the manufacturer's microarray scanner and quantification software (CGH analytics, Agilent) and were sorted by genomic location using the NCBI build 36 (UCSC hg18 March 2006) of the human genome. The sorted data were grouped into 5-probe sliding window bins, and the mean log2 ratios for each bin were determined for use in the subsequent analysis.
AAO was related to log2 ratio using Weibull parametric hazard function regression (survival package in R; http://cran.r-project.org). The 5-probe sliding window size was selected empirically based on extensive experience in clinical CNV detection which utilizes confirmation by fluores-cent in situ hybridization (FISH). We performed a genomewide correction for multiple testing by repeating the analysis 1,000 times permuting patient AAO. For each permutation the maximum geometric mean of Ϫlog p values for 20 consecutive bins was determined. The use of 20 consecutive bins incorporates the dependence between the consecutive 5-probe sliding windows as well as our desire to focus on regions that exhibit a consistent association across a genomic region. Only 32 of 1,000 random permutations generated a set of contiguous results where the geometric mean of p values was as strong as that found for the 14q11.2 interval.
In order to rule out spurious association from a rare CNV present in only one individual at the extremes of the AAO spectrum we calculated signal variance for each bin. We determined the 99th percentile of these variances and we identified all regions that exceeded this variance threshold (n ϳ 2,400). We applied the 99th percentile variance filter as a second dimension complementary to the p value for hazard regression analysis to prioritize highly variable AAO-associated regions for replication analysis. Furthermore, we performed segmentation analysis on the cohort using the Agilent ADM2 algorithm to confirm that the associations observed in the hazard analysis correspond to actual segmental events. We required that the CNV is present in at least 5% of the cohort (2 or more individuals).
Replication cohort. A replication cohort (n ϭ 507 subjects with AD) was evaluated using Affymetrix array (n ϭ 243) and multiplex ligation-dependent probe amplification (MLPA) 14 (n ϭ 264) (table e-2). The replication cohort sample size was determined based on the effect size from the discovery cohort taking into account the variance of AAO due to the APOE4, as the replication cohort included all APOE4 genotypes. Power analysis for the replication study was performed using the time-to-event statistical power calculation method spower from the survival analysis utility R library Hmisc (http://cran.r-project.org/). We used the observed AAO data from the interval defined in the preliminary data to simulate AAO values for such CNV data (1,000 replicates). For a sample size of 350, we achieve a power of 90% in our simulations.
CN genotype for 243 patients was assayed on a Genome-Wide Human SNP Array 6.0 (Affymetrix). The log2ratios were generated in the Genotyping Console 3.0.1 software after regional GC correction using 78 concomitantly ascertained normal controls as reference. A Gaussian mixture model was applied to the normalized mean intensities to analyze CN state (appendix e-1 and figure e-1). The CN calls were validated by MLPA (MRC Holland) in a subset of subjects and in all subjects with the 5ϩ CN state (figure e-2). CN genotype for the subsequent 264 subjects was assayed by the high throughput MLPA assay. CN calls were also made by use of a Gaussian mixture model (appendix e-1 and figure e-1). The distribution of CN states within the assays is depicted in table e-3.
AAO was related to the inferred CNV dosage of the 14q11.2 region detected in the discovery cohort (Variation_0316; http://projects.tcag.ca/variation/) using Cox proportional hazard regression (Survival Package in R; http://cran.r-project.org/). We incorporated sex, APOE4 dosage (0, 1, 2), and the interaction between APOE4 dosage and the chromosome 14q11.2 locus CN state as covariates into the regression model.
RESULTS QC and genotyping consistency between
platforms and FISH confirmation. QC measures are detailed in appendix e-1. The CNVs inferred in the replication cohort are depicted in figure 1A in the context of previously observed variants in the Data- base of Genomic Variants. The sizes and location of the CNVs detected in the replication study are in agreement with the reported CNVs. We validated that CN was congruent between the various assays (Agilent Human Genome CGH microarray 244A, Genome-Wide Human SNP Array 6.0 [Affymetrix], and the MLPA) by genotyping a subset of samples by 2 or 3 assays (figure 1, B and C). The unique sequence around the OR4K2 gene allowed us to confirm the CNV by FISH 15 ( figure 1D ). The FISH suggests that up to 3 copies are located on the same chromosome in close proximity. figure 2A and table e-4) (multiple testing corrected p ϭ 0.032). This region also had high log2 ratio variability (top 1%) and segmentation confirmed CNV calls at an allele frequency over 5% ( figure 2B ). The array data heat map for the region (figure 2C) visually illustrates that higher CN (yellow) is associated with earlier AAO (figure 2C). A 10-year difference in median AAO-67 years vs 77 years-was found when comparing high to low CN partitioned cohort (normalized mean log2 ratio Ͼ0 vs Ͻ0).
The interval includes a multiallelic cluster of overlapping CNVs with various breakpoints (figure 1A and figure e-2). The association signal comes from olfactory receptor gene cluster in the region where OR4M1, OR4N2, OR4K2, OR4K5, and OR4K1 are located. The summary test statistics (Weibull model) for the region are summarized in table 1. The complete set of hazard function outcomes with Ϫlog_ e p Ͼ 7 depicted in the Manhattan plot are summarized in table e-4. The chromosome 14q11.2 region is the only region that survived multiple testing correction and fulfilled our a priori significance filter settings (allele frequency Ͼ5% and variance in Ͼ99th percentile).
Replication cohort. The Cox proportional hazard analysis confirmed the association of CNV varia-tion_0316 dosage on chromosome 14q11.2 with AAO of AD ( p ϭ 0.03) in the replication cohort (tables 1 and 2). The analysis also replicated significant AAO association of APOE 4/4 reported in the literature. No interaction between APOE and the CN locus was identified by the regression; no gender effects were detected. The dosage association of the olfactory receptor gene cluster on AAO of disease is presented in the box plot ( figure 3A) . The time to event survivorship curves for the various CN states depicts the percentage of subjects diagnosed by age for each CN state ( figure 3B ). The relative risk (RR) for onset of AD is proportionally increased 1.12-fold for each one-copy increase of the olfactory receptor CN state (table 1). The association of the 14q locus appears to be independent of and in addition to the effect of APOE.
The most striking association signal appears to originate from the 5ϩ CN state on all APOE back-
Figure 2
Variation_0316 association with age at onset (AAO) of Alzheimer disease in the discovery cohort
The discovery study is summarized in figure 2 . The -log e p values for Z scores from the hazard function regression performed on the array data using a 5-probe sliding window are plotted as a function of genomic location (A). In panel B, the -log e p values are plotted against the variance (surrogate for allele frequency and number of alleles). The variance filter serves to exclude spurious association from a rare copy number variant not highly observed in the cohort and present in only one or a few individuals at the extremes of the AAO spectrum (B). (C) Age information and array data for AAO is represented in the red and blue color bar to the side of each array data heat map. Each cell in the subject age bar is adjacent to the row of the array data heat map for that subject. Red represents younger subjects, while blue represents older subjects in a linear scale from age 55 to age 84. The blue and yellow heat maps convey copy number array data for the region. Each blue-yellow row represents a subject and each column represents the data for a single oligonucleotide probe. Genomically adjacent oligos are shown next to each other from left to right. The inclusion criteria aimed to capture a broad range of AAO to increase power which potentially resulted in enrollment of early-onset familial AD cases. We did not screen the cohort for mutations in APP, PSEN1, and PSEN2 as cohort studies have demonstrated that mutations in these genes are seldom detected in patients who do not have an autosomal dominant family history of AD. However, in order to further confirm the association, we reanalyzed the subset of the replication cohort with AAO over 60. The olfactory receptor locus remained associated with AAO in the categorical model (RR ϭ 1.72, CI 1.01-2.96, and p ϭ 0.049) in the reduced dataset (n ϭ 439).
In the Affymetrix set (n ϭ 243) we used the complete SNP dataset ascertained from the Genome-Wide Human SNP Array 6.0 (Affymetrix) to assess the possibility of population substructure confounding CN state. The population substructure analysis was performed by principal component analysis with the Eigenstrat package for the first 10 principal components. 16 The projected values for the samples were then plotted against each other for the first 2 components ( figure e-3) .
DISCUSSION AD is one of the most significant public health problems and likely to increase in its burden to society, considering projected increases in longevity and number of aging individuals. 1 Delay of AAO of AD could result in marked decrease in prevalence and therefore AAO is an important attribute of disease and a desired therapeutic target. Although AAO can only be estimated, the usefulness of determining symptom onset via the single question inquiry method has been demonstrated by the identification of the influence of the APOE4 allele on AAO. 17 We estimated AAO by 2 methods, the single question inquiry and a validated structured interview with landmark event to facilitate recall of the surrogate historian. 13 The Spearman correlation of the 2 methodologies was significant (Spearman correlation rho ϭ 0.9409, p ϭ 2.2 ϫ 10 Ϫ16 ; CI 0.90 -0.97) and outlier and residual analysis showed no systematic deviation between the 2 methods.
We have undertaken a cases-only CN variation genome-wide association study with AAO of AD and have detected association of gene dosage of the olfactory receptor region on chromosome 14q11.2 with AAO of AD. The replication cohort confirmed the association. Moreover, this analysis showed the CN association to be independent of and in addition to the association observed for APOE4. The CNV contributing to the association signal harbors an olfac- Table 1 Variation_0316 dosage association with AAO of AD: Weibull hazard outcome in the discovery set and Cox proportional hazard outcomes in the replication cohort tory receptor gene cluster, which contains plausible candidate modifier genes in disease pathomechanism in agreement with clinical and neuropathologic observations. The allele frequencies of the CNV region identified are comparable to prior reports, 18 and the allele frequencies in the replication study are consistent with detection of the association between CN and AAO in the discovery cohort. Applying a categorical model to the replication dataset yielded a more significant association, suggesting that the 5ϩ CN state confers the highest risk.
Although we detected all CN states in the controls as well (table e-5), the sample size is small and the study is not designed for case-control association. In fact, our study design is statistically powerful because the cases-only approach eliminated the mis-classification bias in this late-onset disease with agedependent penetrance. However, the cases-only design is a limitation of our study. Sample size calculations for a case-control association based on an allele frequency of 0.04 (the observed frequency of CN5ϩ high risk state) and using an estimated odds ratio (OR) of 1.5 (effect size for the CN5ϩ state) suggest that a sample size of 1,800 cases and 1,800 controls are required to achieve a power of 0.8 to detect an association. This sample size is beyond the scope of this study.
Previous studies [19] [20] [21] investigating the genetics of AAO of AD used SNP datasets, and thus our CNV approach is complementary to these studies. The prior SNP association studies are likely to have lacked sensitivity to detect this locus because of its This study shows an association of CN varia-tion_0316 and AAO, and does not lead us to causal genes per se. However, the association signal arising from a multiallelic CNV locus and the gene dosage association suggest that the gene content of the CNV including the olfactory receptor cluster is a potential modifier of AAO in AD. Prospective cohort studies established the risk olfactory deficit confers for the development of cognitive decline. A prospective study of 1,920 cognitively normal subjects found a significant association between olfactory impairment at baseline and 5-year incidence of cognitive impairment (OR ϭ 6.62, CI ϭ 4.36 -10.05). 23 Another study of 1,604 older adults without dementia found that women with anosmia who possessed at least one APOE4 allele had an OR of 9.71 for development of cognitive decline over the ensuing 2 years, compared with an OR of 1.9 for women with no olfactory dysfunction and at least one such allele. 24 Neuropathologic series have found marked cell loss in the olfactory bulb and anterior olfactory nucleus and the presence of disease-related pathology: neuritic plaques and neurofibrillary tangles in these structures. 25 Whether loss of olfaction is a primary or secondary phenomenon in the pathomechanism of AD is unclear; however, this genetic observation raises the possibility for its role in modifying the AAO.
Although the allele frequency is low, in a disease with a prevalence of 5.3 million a frequency of 4% translates to over 200,000 subjects with the high CN state affected by the disease. Patients with AD with the earliest AAO represent the most desired group for intervention with disease-modifying therapy. Pathogenic CNVs may be more amenable to therapy than other types of genetic variation. In contrast to mutation events resulting in loss of function or toxic gain of function, CNVs alter gene dosage, allowing modification by small molecules which may offset the dosage effects. 26 For example, the CMT1A duplication rat model treated with a progesterone antagonist achieved clinical and pathologic improvement even by partial correction of gene expression by epigenetic modification. 27 If confirmed, evaluation of olfactory receptor CN may lead to both earlier detection and potential disease-modifying therapy, both of which could have a major impact on the public health burden of AD.
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